The Study of Qishenyiqi Drop Pills in Improving the Prognosis of Heart Failure Patients

Exclusion Criteria

• •Acute decompensated HF with hemodynamic instability, mechanical hemodynamic support or invasive mechanical ventilation within 14 days of randomization, using intravenous positive inotropic drugs, vasoactive drugs and intravenous diuretics within 7 days before randomization.
• •Poorly controlled hypertension, defined as resting systolic blood pressure≥180mmHg and /or diastolic blood pressure ≥110mmHg assessed on two separate occasions prior to randomization.
• •Liver transaminase (ALT or AST), bilirubin more than 3 times the upper limit of normal not caused by heart failure, glomerular filtration rate\<15ml/min/1.73m2.
• •Hemoglobin concentration ≤ 9.0g/dl and/or have blood system disease.
• •Valvular heart disease, congenital heart disease without surgery.
• •Cardiac shock.
• •Hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, other secondary and invasive cardiomyopathy.
• •Active myocarditis.
• •Constrictive pericarditis, other pericardial diseases.
• •Syncope within 3 months.
• •Symptomatic bradycardia or II or III degrees heart block without a pacemaker.
• •Ventricular arrhythmias affecting hemodynamics.
• •Cardiac resynchronization therapy implanted pacemaker (CRT-P) or cardiac resynchronization therapy defibrillators (CRT-D) within 6 months, or upgrade the existing conventional pacemaker or implantable implantable defibrillator (ICD) to the CRT device, or have the intention to implant similar devices.
• •Occurred within 3 months: acute coronary syndrome, stroke, transient ischemic attack; Heart, carotid artery or other large vascular surgery; Percutaneous coronary intervention (PCI) or carotid artery angioplasty, CABG or other cardiac surgery.
• •Major surgery within 6 months prior to randomization.
• •Has a history of heart transplantation or are waiting for transplants or using left ventricular assist device (LVAD) or have intention to heart transplant (waiting for transplants) or implant the VAD.
• •Severe chronic obstructive pulmonary disease, pulmonary heart disease, sever pulmonary vascular disease, pulmonary hypertension caused by autoimmune disease, any type of severe pulmonary hypertension.
• •History of major organ transplant (such as lung, liver, heart, bone marrow, kidney).
• •Patients with serious primary diseases of liver, kidney, hematopoietic system, nervous system, endocrine system, and patients with cancer or mental illness.
• •Life expectancy is less than 1 year.
• •Known allergy to any study drug.
• •Participants in other clinical studies within 1 month.
• •Patients who are taking Chinese medicine and proprietary Chinese medicine with similar ingredients of QSYQ.
• •Women who have developed pregnancy (pregnancy test positive) or during lactation; women of childbearing age have not taken adequate contraceptive measures.
• •According to the researchers, patients could not complete the study or fail to comply with the requirements of the study (due to management or other reasons).